Literature DB >> 34339680

Biomarkers in the prognostic evaluation of ischemic stroke: Is there benefit in the measurements of TREM-1 and TREM-2 in the acute phase?

Fabiane Neiva Backes1, Andressa de Souza2, Marino Muxfeldt Bianchin3.   

Abstract

BACKGROUND AND
PURPOSE: Triggering receptors expressed on myeloid cells 1 and 2 (TREM-1 and TREM-2) are cell surface receptors important for modulation of microglia immune response. In this study, we evaluate serum levels of TREM-1 and TREM-2 as potential biomarkers in acute ischemic stroke (AIS).
MATERIAL AND METHODS: Prospective cohort study of 50 patients with AIS admitted at our hospital. Serum TREM-1 and TREM-2 was evaluated within 24 h of the acute event and on the third and fifth days after the stroke. Neurological stroke severity and global disability were determined with the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) at the same three times and at the time of hospital discharge.
RESULTS: TREM-1 and TREM-2 levels were elevated in stroke. TREM-1, but not TREM-2, exhibited correlations with NIHSS and mRS within 24 h (NIHSS and TREM-1: rS = 0.31, p = 0.029; mRS and TREM-1: rS = 0.32, p = 0.023). The serum level of TREM-1 within 24 h correlated with the neurological outcomes at hospital discharge (NIHSS and TREM-1: p = 0.021; mRS and TREM-1: p = 0.049). The serum concentrations of TREM-1 protein within 24 h after stroke was significantly higher in patients with poor outcome (mRS > 2) at hospital discharge (p = 0.021). After Exact Logistic Regression, large segmental stroke (O.R. = 4.14; 95CI = 1.07-16.09; p = 0.040) and initial sTREM levels (O.R. = 1.02; 95CI 1.00-1.04; p = 0.045) remained independent prognostic factors for AIS poor outcome (mRS > 2).
CONCLUSION: In our study, TREM-1 and TREM-2 were significantly increased in AIS. Early elevation of TREM-1 correlated with stroke severity and it was an independent prognostic factor for stroke outcome.
Copyright © 2021 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Blood biomarkers; Cerebral ischemic stroke; Outcome; Triggering receptor expressed on myeloid cells type 1 (TREM1); Triggering receptor expressed on myeloid cells type 2 (TREM2)

Mesh:

Substances:

Year:  2021        PMID: 34339680     DOI: 10.1016/j.clinbiochem.2021.07.016

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  3 in total

1.  The relationship between vitamin D receptor gene and TREM-1 gene polymorphisms and the susceptibility and prognosis of neonatal sepsis.

Authors:  Li Xiao; Shengshun Que; Lei Mu; Rongxiu Zheng
Journal:  J Clin Lab Anal       Date:  2022-03-31       Impact factor: 3.124

Review 2.  The role of triggering receptor expressed on myeloid cells-1 (TREM-1) in central nervous system diseases.

Authors:  Chunyan Zhang; Xugang Kan; Baole Zhang; Haibo Ni; Jianfeng Shao
Journal:  Mol Brain       Date:  2022-10-22       Impact factor: 4.399

Review 3.  The dual function of microglial polarization and its treatment targets in ischemic stroke.

Authors:  Yong Mo; Weilin Xu; Kaijing Fu; Hainan Chen; Jing Wen; Qianrong Huang; Fangzhou Guo; Ligen Mo; Jun Yan
Journal:  Front Neurol       Date:  2022-09-23       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.